Fig. 2: Expression of DSB repair genes predicts survival of AML.
From: DNA damage response genes as biomarkers of therapeutic outcomes in acute myeloid leukemia patients
A, B Kaplan-Meier plots showing the difference in survival between subjects with high versus low scaled and normalized values of the DSB repair genes in the BEAT AML 2.0 (A) and TARGET-recurrent AML (B) datasets. High versus low cut points were determined via Thiele and Hirschfield’s method to find an optimal outcome-based cut point, survival.
